SCHEMBL3058235

SCHEMBL3058235

CN(C(=O)c1cccc(C(F)(F)F)c1)[C@H](CCN)Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.47
OPRM1 P35372 2/20 0.46
OPRL1 P41146 1/20 0.46
KIF11 P52732 1/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
USP2 O75604 2/20 0.43
CYP3A4 P08684 2/20 0.43
HTR2A P28223 2/20 0.43
HTR2C P28335 2/20 0.43
HTR2B P41595 2/20 0.43
NR1I2 O75469 1/20 0.43
ADRB1 P08588 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
CHRM3 P20309 1/20 0.43
SLC6A2 P23975 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060252 1.00 TRPM8 (0.47) TRPM8OPRM1OPRL1KIF11PPARG
SCHEMBL3060314 0.87 MEN1 (0.46) TRPM8KIF11PPARGPPARAHTR1A
SCHEMBL3048428 0.87 MEN1 (0.46) TRPM8KIF11PPARGPPARAHTR1A
SCHEMBL3060247 0.87 TRPM8 (0.49) TRPM8OPRM1OPRL1PPARGPPARA
SCHEMBL3058232 0.87 TRPM8 (0.49) TRPM8OPRM1OPRL1PPARGPPARA
SCHEMBL3045271 0.84 HTR1A (0.47) HTR1AADRA2CHCRTR1HCRTR2ALDH1A1
SCHEMBL3059938 0.84 HTR1A (0.47) HTR1AADRA2CHCRTR1HCRTR2ALDH1A1
SCHEMBL3058403 0.84 HTR1A (0.47) HTR1AADRA2CHCRTR1HCRTR2ALDH1A1
SCHEMBL3048416 0.84 HCRTR1 (0.51) TRPM8HTR2CHCRTR1HCRTR2HDAC8
SCHEMBL3058136 0.84 HCRTR1 (0.51) TRPM8HTR2CHCRTR1HCRTR2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES NOVARTIS AG (CH) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES CYP11B2, CYP11B1, BBC3 TRPM8 1326/4885OPRM1 277/4885OPRL1 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.